Form 4: Avidity Biosciences Officer Sells Shares for Tax Obligations

Avidity Biosciences' Chief Program Officer, Kathleen P. Gallagher, sold 188 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, Inc., reported a sale of 188 shares of common stock.
• The transaction occurred on September 2, 2025, at a price of $47.42 per share.
• This sale was a "sell-to-cover" transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) on August 30, 2025.
• The sale was not a discretionary trade by Ms. Gallagher and was executed pursuant to an instruction letter intended to satisfy the affirmative defense conditions of Rule 10b5-1.
• Following this transaction, Ms. Gallagher beneficially owns 50,204 shares of Avidity Biosciences common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary 'sell-to-cover' transaction for tax purposes, which is a common occurrence for executives receiving equity compensation and does not reflect a change in management's outlook or confidence in the company.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook, as it pertains solely to an insider transaction.

Management Comments

• The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on August 30, 2025, and the sale of the resulting shares of common stock on September 2, 2025.
• This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person.
• The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Industry Context

This routine insider transaction, a 'sell-to-cover' for tax obligations, is a common occurrence across all industries for executives receiving equity compensation. It does not reflect any specific industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in insider sentiment or company fundamentals.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell-to-cover' transaction by a Chief Program Officer to satisfy tax obligations upon RSU vesting. Such transactions, especially when executed under a Rule 10b5-1 plan, do not provide new fundamental information about the company's operational performance, strategic direction, or management's confidence. Therefore, it does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate as no new actionable insights for buying or selling are presented.

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Stock Sale, Sell-to-cover, RSU, Kathleen P. Gallagher, Rule 10b5-1